Martin Shkreli blames ‘unjust’ arrest on drug price hikes

The pharmaceutical entrepreneur facing US charges of securities fraud said he had been the target of authorities for his drug-price hikes and over-the-top public persona.

Martin Shkreli has been charged for engaging in what US prosecutors said was a Ponzi-like scheme at his former hedge fund MSMB Capital Management and Retrophin, a firm he headed before he took the helm of Turing Pharmaceuticals.

Earlier this year, after buying a 60-year-old drug called Daraprim, Turing raised the price overnight to $750 a tablet from $13.50.